Northern Lifeline Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Northern Lifeline Pharmaceutical Export Portfolio Dataset — 3 Products, $214.4K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Northern Lifeline — Pharmaceutical Exporter Profile (2026) | 3 Products, $214.4K Trade | TransData Nexus

Northern Lifeline

Indian Pharmaceutical Exporter · Antimalarial & Antiparasitic Specialist · $214.4K Total Trade · DGFT Verified

Northern Lifeline is an Indian pharmaceutical exporter with a total trade value of $214.4K across 3 products in 3 therapeutic categories. Based on 141 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ivermectin ($128.3K), Valacyclovir ($83.6K), Canagliflozin ($2.4K).

Northern Lifeline — Export Portfolio & Destination Treemap

Northern Lifeline pharmaceutical export portfolio — 3 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Northern Lifeline? — Company Overview & Market Position

Northern Lifeline is an Indian pharmaceutical exporter specializing in the production and distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2018, the company is headquartered at 27 Second Floor Pearl Omex NSP, Pitampura, New Delhi, India. The ownership structure is not publicly disclosed, and the Corporate Identification Number (CIN) is not available. As of the latest available data, Northern Lifeline has a total export value of $214,000 USD, with 141 shipments recorded. The company exports three products across three therapeutic categories, with a portfolio concentration where the top three products account for 100% of the export value. The employee count and website information are not publicly disclosed.

What Does Northern Lifeline Export? — Product Portfolio Analysis

Top Products by Export Value

1Ivermectin$128.3K 2Valacyclovir$83.6K

Product Portfolio — Top 3 by Export Value

Northern Lifeline exports 3 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ivermectin	Antimalarial & Antiparasitic	$128.3K	83	1.5%	15
2	Valacyclovir	Antivirals	$83.6K	54	0.1%	13
3	Canagliflozin	Advanced Diabetes Medications	$2.4K	4	0.3%	12

Northern Lifeline exports 3 pharmaceutical products across 3 therapeutic categories with a total export value of $214.4K. The top category is Antimalarial & Antiparasitic (59.9% of portfolio), followed by Antivirals (39.0%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Northern Lifeline — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Specific details regarding Northern Lifeline's manufacturing facilities, including locations, capacities, and specializations, are not publicly available. The company's export data indicates a focus on finished pharmaceutical formulations, but without access to proprietary information, a comprehensive assessment of their manufacturing capabilities cannot be provided.

3Key Leadership

Information about the key leadership of Northern Lifeline, including the CEO/MD, CFO, and other executives, is not publicly disclosed. Without access to proprietary data, a detailed analysis of the company's leadership structure cannot be provided.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Northern Lifeline Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Northern Lifeline's export data indicates shipments to various international markets, including the Philippines, Singapore, and Mauritius. However, specific details regarding regulatory filings, approvals, and market access status in the United States, European Union, United Kingdom, Australia, and Japan are not publicly available. Without access to proprietary information, a comprehensive analysis of the company's presence in these regulated markets cannot be provided.

2Emerging Markets

Northern Lifeline's export data indicates shipments to the Philippines, suggesting a presence in emerging markets. However, specific details regarding the company's penetration in Africa, Latin America, and Southeast Asia, as well as WHO prequalification enabling access, are not publicly available. Without access to proprietary information, a comprehensive assessment of the company's activities in these regions cannot be provided.

3Geographic Strategy

Northern Lifeline's export data indicates shipments to markets such as the Philippines, Singapore, and Mauritius. However, without access to proprietary information, a detailed assessment of the company's geographic diversification, concentration risk, and strategic direction cannot be provided.

Northern Lifeline — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Northern Lifeline's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. Without access to proprietary information, a comprehensive analysis of the company's FDA status cannot be provided.

2WHO & EU GMP

Information regarding Northern Lifeline's WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not publicly available. Without access to proprietary information, a detailed assessment of the company's compliance with these international standards cannot be provided.

3CDSCO & Indian Regulatory

Specific details regarding Northern Lifeline's Central Drugs Standard Control Organization (CDSCO) manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly available. Without access to proprietary information, a comprehensive analysis of the company's compliance with Indian regulatory requirements cannot be provided.

Northern Lifeline — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Northern Lifeline operates in the pharmaceutical export sector, focusing on finished pharmaceutical formulations. While specific competitors are not identified, the company faces competition from other Indian pharmaceutical exporters offering similar products. Without access to proprietary information, a comprehensive analysis of the competitive landscape, including market share comparisons and head-to-head analysis, cannot be provided.

2Key Differentiators

Northern Lifeline's export data indicates a focus on finished pharmaceutical formulations, including Ivermectin, Valacyclovir, and Canagliflozin. However, without access to proprietary information, a detailed assessment of the company's unique strengths, competitive advantages, and product portfolio distinctions cannot be provided.

3Strategic Position

Northern Lifeline's export data indicates a focus on finished pharmaceutical formulations, with a portfolio concentration where the top three products account for 100% of the export value. However, without access to proprietary information, a detailed assessment of the company's current strategic direction, including its focus on generics, specialty drugs, biosimilars, or Contract Development and Manufacturing Organization (CDMO) services, and its future outlook cannot be provided.

Buyer Due Diligence Brief — Evaluating Northern Lifeline as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Northern Lifeline's export data indicates shipments to markets such as the Philippines, Singapore, and Mauritius. However, without access to proprietary information, a comprehensive assessment of the company's overall track record, export volume and consistency, and reliability indicators cannot be provided.

2Certifications to Verify

Importers should verify the following certifications when considering Northern Lifeline as a supplier:

FDA Registration: Confirm the company's FDA facility registration status through the FDA's official website.

WHO-GMP Certification: Verify the company's compliance with WHO Good Manufacturing Practice standards through the World Health Organization's official website.

EU GMP Certification: Check the company's adherence to EU Good Manufacturing Practice standards through the European Medicines Agency's official website.

Frequently Asked Questions — Northern Lifeline

How many pharmaceutical products does Northern Lifeline export from India?

Northern Lifeline exports 3 pharmaceutical products across 3 therapeutic categories. The top exports are Ivermectin ($128.3K), Valacyclovir ($83.6K), Canagliflozin ($2.4K). Total export value is $214.4K.

What is Northern Lifeline's total pharmaceutical export value?

Northern Lifeline's total pharmaceutical export value is $214.4K, based on 141 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Northern Lifeline cover?

Northern Lifeline exports across 3 therapeutic categories. The largest are Antimalarial & Antiparasitic (59.9%, 1 products), Antivirals (39.0%, 1 products), Advanced Diabetes Medications (1.1%, 1 products).

Get Full Northern Lifeline Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.